Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanxi Kangbao Biological Product Co Ltd, Inst Pathogen Biology CamsfiledCriticalShanxi Kangbao Biological Product Co Ltd
Priority to CL2019002928ApriorityCriticalpatent/CL2019002928A1/en
Publication of CL2019002928A1publicationCriticalpatent/CL2019002928A1/en
Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy.